Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.

Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.

The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.

Of the big oncology deals since 2016, there are still plenty that could go either way.

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.

Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.

Lifileucel heads up the list of upcoming US FDA catalysts.